Healthcare Industry News: Pulse Oximetry
News Release - November 8, 2006
Drager Medical and Masimo Announce Expanded RelationshipDrager Medical adopts Masimo Rainbow SET as its standard oximetry platform. The two companies also released each other from any potential patent infringement claims on Pulse Oximetry.
IRVINE, Calif., Nov. 8 (HSMN NewsFeed) -- Drager Medical AG & Co. KG today announced that it has expanded its relationship with Masimo and will integrate Masimo Rainbow SET platform as its principal Pulse Oximetry technology. The Rainbow SET platform offers Masimo SET Read-Through Motion and Low Perfusion Pulse Oximetry plus upgradeability to add other parameters in the future. Upgrades are available today for carboxyhemoglobin (carbon monoxide) and methemoglobin and others are planned for the future. Drager Medical will be incorporating Masimo Rainbow SET into major acute care products. For future product developments, Drager Medical will replace its Oxisure+ oximetry with Masimo technology. This agreement between Drager Medical and Masimo also constitutes a release of each other from any potential patent infringement claims relating to Pulse Oximetry.
Dr. Wolfgang Reim, President and CEO of Drager Medical stated, "We are excited to be able to extend our existing relationship and again be one of the first companies to provide our customers with the latest advancements in noninvasive patient monitoring technology. Masimo SET is clearly the gold standard in motion tolerant Pulse Oximetry technology and with its new Rainbow Technology Masimo extends the reach of its technology to new important parameters. Drager Medical and Masimo have enjoyed a great partnership that we are very happy to expand."
Joe E. Kiani, Chairman and CEO of Masimo stated, "We greatly value our relationship with Drager Medical and are happy to be expanding our relationship with this new agreement. Drager Medical's leadership in patient monitoring and therapeutic systems is well recognized by numerous customers around the world. We are delighted to see Drager Medical taking Masimo Rainbow SET to its customers, and thereby improving care of millions of patients."
About Drager Medical
Drager Medical AG & Co. KG is one of the world's leading manufacturers of medical equipment, the largest division of Dragerwerk AG (history dates back to 1889) and a 65:35 joint venture company between Dragerwerk AG and Siemens AG. The global Company offers products, services and integrated CareArea(TM) Solutions throughout the patient care process -- Emergency Care, Perioperative Care, Critical Care, Perinatal Care and Home Care. With headquarters in Lubeck, Germany, Drager Medical employs nearly 6,000 people worldwide, around half of whom work in customer sales & services. R&D and production are located in Lubeck, Germany; Best, Netherlands; Telford, PA, and Andover, MA, USA; and Shanghai, China. The Company has sales and service subsidiaries in almost 50 countries and is represented in more than 190 countries. Drager Medical provides innovative solutions for acute patient care, which are the result of a clear focus on core competencies, a close dialog with customers, over a century of experience in the market, and continuous investment in R&D. Additional information is available on the Company's website www.draeger.com
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion Pulse Oximetry, known as SET, and with it virtually eliminated false alarms and increased Pulse Oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations -- establishing the technology as the "gold standard" Pulse Oximetry and substantially contributing to improved patient outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life- threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.